Newer insulin analogs: Advances in basal insulin replacement

Diabetes, Obesity and Metabolism

Volumn 15, Issue SUPPL. 1, 2013, Pages 6-10

  Zinman, Bernard ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b Leadership Sinai Centre for Diabetes   (Canada)

Author keywords

Basal insulin; Insulin degludec; Investigational; Nocturnal hypoglycaemia; PEGylated long acting basal insulin; Type 1 diabetes; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN DEGLUDEC; INSULIN GLARGINE; INSULIN PEGLISPRO;

BLOOD GLUCOSE MONITORING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 84874538906     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12068     Document Type: Review

References (37)

1. Zinman B. The physiologic replacement of insulin. An elusive goal. N Engl J Med 1989; 321: 363-370.
2. Rosenstock J, Bergenstal RM, Blevins TC, etal. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study. Diabetes Care. 2012. Nov 27. [Epub ahead of print] DOI: 10.2337/dc12-0067.
3. Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000; 34: 915-923.
4. Hansen R, Cutler GB, Vick A et al. LY2605541: Leveraging hydrodynamic size to develop a novel basal insulin (Abstract 896-P). American Diabetes Association 72nd Annual Scientific Sessions, June 8-12, 2012, Philadelphia, PA.
5. Sinha VP, Howey DC, Soon DKW et al. Single-dose pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 in healthy subjects (Abstract 1063-P). American Diabetes Association 72nd Annual Scientific Sessions. June 8-12, 2012, Philadelphia, PA.
6. Meloun B, Moravek L, Kostka V. Complete amino acid sequence of human serum albumin. FEBS Lett 1975; 58: 134-137.
7. Heise T, Howey DC, Sinha VP, Choi SL, Mace KF. Steady-state pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 dosed once-daily (QD) in patients with type 2 diabetes mellitus (Abstract 1000-P). American Diabetes Association 72nd Annual Scientific Sessions. June 8-12, 2012; Philadelphia, PA.
8. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012; 35: 2140-2147.
9. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
10. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.
11. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
12. Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes 2012; 5: 191-204.
13. Birkeland KI, Home PD, Wendisch U et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34: 661-665.
14. Zinman B, Fulcher G, Rao PV et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011; 377: 924-931.
15. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569.
16. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.
17. Murray P, Chune GW, Raghavan VA. Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials. Curr Atheroscler Rep 2010; 12: 432-439.
18. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
19. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
20. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
21. Karter AJ, Subramanian U, Saha C et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care 2010; 33: 733-735.
22. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabet Med 2006; 23: 750-756.
23. Holman RR, Farmer AJ, Davies MJ et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
24. Evans M, Khunti K, Mamdani M. Health-related quality of life associated with daytime and nocturnal hypoglycemic events: a time trade-off survey (Oral 135). American Diabetes Association 72nd Annual Scientific Sessions. June 8-12, 2012, Philadelphia, PA.
25. Garber AJ, King AB, Del Prato S et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
26. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010; 33: 240-245.
27. Garg SK, Gottlieb PA, Hisatomi ME et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004; 66: 49-56.
28. Le Floch JP, Levy M, Mosnier-Pudar H et al. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009; 32: 32-37.
29. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007; 24: 27-34.
30. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
31. Mathieu C, Hollander P, Miranda-Palma B. Insulin degludec allows for flexible daily dosing in type 1 diabetes, providing equal glycemic control with less nocturnal hypoglycemia than insulin glargine over 52 weeks (Abstract 2162). American Diabetes Association 72nd Annual Scientific Sessions. June 8-12, 2012; Philadelphia, PA.
32. Russell-Jones D, Del Prato S, Gall MA. Insulin degludec results in consistently lower rates of nocturnal hypoglycemia despite lower FPG levels compared to insulin glargine in seven trials with T1DM or T2DM (Abstract 2395). American Diabetes Association 72nd Annual Scientific Sessions. June 8-12, 2012; Philadelphia, PA.
33. Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 2012; 19: 93-96.
34. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34: 1249-1257.
35. Shaya FT, Yan X, Lin PJ et al. US trends in glycemic control, treatment, and comorbidity burden in patients with diabetes. J Clin Hypertens (Greenwich). 2010; 12: 826-832.
36. Bergenstal R, Bhargava A, Jain R, et al. 200 u/ml Insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve people with type 2 diabetes. AACE 21st Annual Scientific & Clinical Congress. May 23-27, 2012; Philadelphia, PA. Abstract #207.
37. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.